Tratamento da hipertensão arterial com olmesartana medoxomila em escalonamento

Gomes, Marco Antônio Mota; Feitosa, Audes Diógenes de Magalhães; Oigman, Wille; Ribeiro, José Márcio; Moriguchi, Emílio Hideyuki; Saraiva, José Francisco Kerr; Précoma, Dalton Bertolim; Ribeiro, Artur Beltrame; Amodeo, Celso; Brandão, Andréa Araújo

doi:10.1590/s0066-782x2008001500008

Cited by 2 publications

(2 citation statements)

References 10 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…23 Recently, evidence from the literature has suggested that the triple combination of OM, AML and HCTZ is an effective and safe treatment option, because it involves drugs whose mechanisms of action are complementary and synergic. [24][25][26][27][28][29][30][31][32][33][34] …”

Section: Clinical Studiesmentioning

confidence: 99%

“…That suggests that most stage 2 patients need combined therapy to achieve BP goals (Table 1). 30 The Benibest study (Efficacy and Safety of Olmesartan Medoxomil in Stage 1 and 2 Essential Hypertension Study) 24 assessed 144 individuals for the use of OM in a treatment algorithm in four steps as follows: (i) monotherapy (20 mg); (ii-iii) association and OM + AML + HCTZ 40/10/25 mg. In that study, the greatest reductions (36.1 mmHg) in SBP were observed in the group on OM + AML + HCTZ 40/10/25 mg. Those patients also had the highest baseline BP levels (172.9/103.2 mmHg), and 46.3% of them reached BP goals.…”

Section: Efficacymentioning

confidence: 99%

See 1 more Smart Citation

Olmesartan-Amlodipine-Hydrochlorothiazide in Fixed Combination for the Treatment of Hypertension

Gomes¹,

Paiva²,

Campana³

et al. 2012

Clinical Medicine Reviews in Vascular Health

View full text Add to dashboard Cite

Abstract:The guidelines and consensus documents on hypertension management have emphasized the need for a better arterial hypertension (AH) control, and, thus, have recommended an optimized treatment, which usually requires the combined use of drugs that block different mechanisms responsible for blood pressure (BP) increase. For stage 2 and 3 hypertensives, the association of two drugs is mandatory, and if the BP goal is not attained, the association of a third drug is the preferential option. For high CV risk patients, the current tendency is to block the renin-angiotensin-aldosterone system (RAAS) with an angiotensin-converting-enzyme inhibitor (ACEI) or with an angiotensin II type 1 receptor blocker (ARB) or even with a direct renin inhibitor (DRI), associated with a calcium channel blocker (CCB). When the BP goal is not reached with this type of association, a diuretic compound is the drug to be added. The triple combination of Olmesartan (OM), amlodipine (AM)L, and hydrochlorothiazide (HCTZ) seems to be one of the most adequate choice, due to the complementary mechanisms of action of their agents. This study aimed at reviewing both the rationale for the combined use of drugs for controlling AH and the results of the clinical trials on the triple association of OM, AML, and HCTZ.

show abstract

Section: Clinical Studiesmentioning

confidence: 99%

Section: Efficacymentioning

confidence: 99%

Olmesartan-Amlodipine-Hydrochlorothiazide in Fixed Combination for the Treatment of Hypertension

Gomes¹,

Paiva²,

Campana³

et al. 2012

Clinical Medicine Reviews in Vascular Health

View full text Add to dashboard Cite

show abstract

Rationale for Triple‐Combination Therapy for Management of High Blood Pressure

Gradman

2010

J of Clinical Hypertension

View full text Add to dashboard Cite

The goals of antihypertensive therapy include optimal reduction in blood pressure (BP) while providing a favorable tolerability profile that promotes long-term adherence to treatment. For most patients with hypertension, these treatment goals cannot be achieved with monotherapy. When instituted early, however, combination therapy results in more rapid control of BP. This approach may facilitate improvements in long-term clinical outcomes, compared with more traditional and time-consuming stepped care and add-on algorithms for the management of hypertension. This review summarizes the rationale behind combination therapy, specifically triple-combination therapy, and discusses which combinations are most likely to result in better BP control, fewer side effects, and reduced risk of target organ damage. Supporting evidence from recent triple-combination therapy trials also is included in the review. Finally, the role of single-pill (fixed-dose) combination therapy in enhancing patient adherence is also discussed. J Clin Hypertens (Greenwich). 2010;12:869-878. 1-4 In a meta-analysis of randomized trials, antihypertensive therapy reduced the risk of stroke by 35% to 40%, the risk of myocardial infarction by 20% to 25%, and the risk of heart failure by >50%.3 Using data from the National Health and Nutrition Examination Survey Epidemiologic Follow-Up Study, Ogden and colleagues 4 determined that a sustained reduction of 10 mm Hg in systolic BP (SBP) over 10 years in patients with stage 1 hypertension and additional CV risk factors would prevent 1 death for every 11 patients treated.The results of epidemiologic studies and landmark clinical trials have been incorporated into evidence-based guidelines for the treatment of hypertension. [5][6][7] These guidelines recommend that management of hypertension should be based on the severity of BP elevation and on the presence of other CV risk factors and comorbidities. In all cases, these guidelines stress that BP should be reduced to <140 ⁄ 90 mm Hg in patients with uncomplicated hypertension and to <130 ⁄ 80 mm Hg in those with diabetes or chronic kidney disease (CKD). More recent recommendations have included patients with established vascular disease and heart failure in the groups requiring the lower BP targets. 8Despite the availability of many effective antihypertensive agents, achieving these BP targets is difficult in many patients. BP is inadequately controlled in one third to one half of patients receiving treatment for hypertension in the United States and Canada and in 40% to 66% of patients with

show abstract

Tratamento da hipertensão arterial com olmesartana medoxomila em escalonamento

Cited by 2 publications

References 10 publications

Olmesartan-Amlodipine-Hydrochlorothiazide in Fixed Combination for the Treatment of Hypertension

Olmesartan-Amlodipine-Hydrochlorothiazide in Fixed Combination for the Treatment of Hypertension

Rationale for Triple‐Combination Therapy for Management of High Blood Pressure

Contact Info

Product

Resources

About